Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

PROSTATE CANCER

Combined advanced prostate cancer treatments: are they additive?

More than 50 clinical trials are currently exploring the combination of immunotherapy and other approved treatments for advanced prostate cancer. The results from a phase II trial of sipuleucel-T with or without radium-223 in patients with metastatic castration-resistant prostate cancer were recently published with intriguing findings.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Barker, H. E., Paget, J. T., Khan, A. A. & Harrington, K. J. The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nat. Rev. Cancer 15, 409–425 (2015).

    CAS  Article  Google Scholar 

  2. 2.

    Deloch, L. et al. Modern radiotherapy concepts and the impact of radiation on immune activation. Front. Oncol. 6, 141 (2016).

    Article  Google Scholar 

  3. 3.

    Dudzinski, S. O. et al. Combination immunotherapy and radiotherapy causes an abscopal treatment response in a mouse model of castration resistant prostate cancer. J. Immunother. Cancer 7, 218 (2019).

    Article  Google Scholar 

  4. 4.

    Kantoff, P. W. et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363, 411–422 (2010).

    CAS  Article  Google Scholar 

  5. 5.

    Parker, C. et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N. Engl. J. Med. 369, 213–223 (2013).

    CAS  Article  Google Scholar 

  6. 6.

    Marshall, C. H. et al. Randomized phase II trial of sipuleucel-T with or without radium-223 in men with bone-metastatic castration-resistant prostate cancer. Clin. Cancer Res. 27, 1623–1630 (2021).

    CAS  Article  Google Scholar 

  7. 7.

    Twardowski, P. et al. Randomized phase II trial of sipuleucel-T immunotherapy preceded by sensitizing radiation therapy and sipuleucel-T alone in patients with metastatic castrate resistant prostate cancer. Cancer Treat. Res. Commun. 19, 100116 (2019).

    Article  Google Scholar 

  8. 8.

    Kwon, E. D. et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 15, 700–712 (2014).

    CAS  Article  Google Scholar 

  9. 9.

    Fizazi, K. et al. Final analysis of the ipilimumab versus placebo following radiotherapy phase III trial in postdocetaxel metastatic castration-resistant prostate cancer identifies an excess of long-term survivors. Eur. Urol. 78, 822–830 (2020).

    CAS  Article  Google Scholar 

  10. 10.

    Heidegger, I. et al. A systematic review of the emerging role of immune checkpoint inhibitors in metastatic castration-resistant prostate cancer: will combination strategies improve efficacy? Eur. Urol. Oncol. https://doi.org/10.1016/j.euo.2020.10.010 (2020).

    Article  PubMed  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Abhishek Srivastava.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Srivastava, A., Shore, N.D. Combined advanced prostate cancer treatments: are they additive?. Nat Rev Urol 18, 325–326 (2021). https://doi.org/10.1038/s41585-021-00459-z

Download citation

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing